Neurotrophin Crosstalk in the Etiology and Treatment of Neuropsychiatric and Neurodegenerative Disease

• Published in: Frontiers in molecular neuroscience Vol. 15; p. 932497
• Main Authors: Joshi, Rajeev, Salton, Stephen R. J.
• Format: Journal Article
• Language: English
• Published: Lausanne Frontiers Research Foundation 15.07.2022; Frontiers Media S.A
• Subjects: Alzheimer's disease; Animal models; Antidepressants; Atrophy; BDNF (brain derived neurotrophic factor); Brain-derived neurotrophic factor; Central nervous system; Cerebrospinal fluid; Etiology; Hippocampus; Ketamine; Kinases; MDD (major depressive disorder); Mental depression; Mental disorders; Nerve growth factor; Neurodegenerative diseases; Neurogenesis; Neuropeptides; Neuroscience; Neurotrophic factors; Therapeutic applications; TLQP-62; TrkB; Vascular endothelial growth factor; VGF
• ISSN: 1662-5099; 1662-5099
• DOI: 10.3389/fnmol.2022.932497

This article reviews the current progress in our understanding of the mechanisms by which growth factors, including brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF), and select neurotrophin-regulated gene products, such as VGF (non-acronymic) and VGF-derived neuropeptides, function in the central nervous system (CNS) to modulate neuropsychiatric and neurodegenerative disorders, with a discussion of the possible therapeutic applications of these growth factors to major depressive disorder (MDD) and Alzheimer’s disease (AD). BDNF and VEGF levels are generally decreased regionally in the brains of MDD subjects and in preclinical animal models of depression, changes that are associated with neuronal atrophy and reduced neurogenesis, and are reversed by conventional monoaminergic and novel ketamine-like antidepressants. Downstream of neurotrophins and their receptors, VGF was identified as a nerve growth factor (NGF)- and BDNF-inducible secreted protein and neuropeptide precursor that is produced and trafficked throughout the CNS, where its expression is greatly influenced by neuronal activity and exercise, and where several VGF-derived peptides modulate neuronal activity, function, proliferation, differentiation, and survival. Moreover, levels of VGF are reduced in the CSF of AD subjects, where it has been repetitively identified as a disease biomarker, and in the hippocampi of subjects with MDD, suggesting possible shared mechanisms by which reduced levels of VGF and other proteins that are similarly regulated by neurotrophin signaling pathways contribute to and potentially drive the pathogenesis and progression of co-morbid neuropsychiatric and neurodegenerative disorders, particularly MDD and AD, opening possible therapeutic windows.